A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer

NCT ID: NCT06267170

Last Updated: 2024-02-20

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 288 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-02-25
• Study Completion Date: 2026-02-25

Brief Summary

This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy

Conditions

SCLC,Extensive Stage

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Interventions

Adebrelimab

Treatment with adbelizumab

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Sign informed consent and join the study voluntarily;

2. Patients diagnosed with extensive small cell lung cancer;

3. Age ≥18 years old;

4. Have at least one measurable lesion (according to RECIST 1.1);

5. The investigators judged that adebrelimab treatment was acceptable;

6. Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception;

Exclusion Criteria

1. Allergic to adebrelimab and its excipients;

2. Patients who have also received other immune drugs or therapies;

3. Patients who are participating in other interventional studies;

4. patients with other malignant tumors;

5. Pregnant or lactating women;

6. The investigator considers that the patient is not suitable to participate in any other conditions of the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Henan Cancer Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Qiming Wang

Chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

SCLC-RWS-001

Identifier Type: -

Identifier Source: org_study_id